Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: Insights from the prospective SIGNS registry

Journal of Public Health (Germany)

Volumn 20, Issue 3, 2012, Pages 289-296

  Kirch, Wilhelm ^a,h   Stangel, Martin ^b   Pittrow, David ^a   Baumann, Ulrich ^b   Fasshauer, Maria ^c   Huscher, Dörte ^d   Hensel, Manfred ^e   Reiser, Marcel ^f   Gold, Ralf ^g   Borte, Michael ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Klinikum St Georg   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Mannheimer Onkologie Praxis   (Germany)

^f PIOH   (Germany)

^g ST JOSEF HOSPITAL   (Germany)

^h DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Immunodeficiency; Management; Neuroimmunology; Observational; Outcomes research; Patient related outcomes; Pharmacoeconomics; Quality of life; Routine care; Therapy

Indexed keywords

IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; CHILD; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE DURATION; DISEASE REGISTRY; FEMALE; GERMANY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOSITIS; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; QUALITY OF LIFE; SCHOOL CHILD; SHORT FORM 36;

EID: 84863491262     PISSN: 09431853     EISSN: 16132238     Source Type: Journal    
DOI: 10.1007/s10389-012-0500-4     Document Type: Article

References (37)

1. Alpert JS (2000) Are data from clinical registries of any value? Eur Heart J 21:1399-1401 (Pubitemid 30636318)
2. Anonymous (1998) SF-36: US population norm values. Internet: http:// www.sf-36.org/research/sf98norms.pdf. Cited 11 November 2011
3. Bellach B, Ellert U, Radoschewski M (2000) Der SF-36 im Bundesgesundheitssurvey: Erste Ergebnisse und neue Fragen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 43:210-216
4. Brennan VM, Salome-Bentley NJ, Chapel HM (2003) Prospective audit of adverse reactions occurring in 459 primary antibodydeficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 133:247-251 (Pubitemid 36918599)
5. Bullinger M, Schmidt S, Petersen C, Erhart M, Ravens-Sieberer U (2007) Methodological challenges and potentials of health-related quality of life evaluation in children with chronic health conditions under medical health care. Med Klin (Munich) 102:734-745 (Pubitemid 47459830)
6. Cohen JA (2008) How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis? Nat Clin Pract Neurol 4:588-589
7. Dalakas MC (2004) The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 102:177-193 (Pubitemid 38887692)
8. Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN (2009) Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 14:93-100
9. Elovaara I, Apostolski S, van Doorn P et al (2008) EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 15:893-908
10. Fazekas F, Lublin FD, Li D et al (2008) Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 71:265-271
11. Gathmann B, Grimbacher B, Beaute J et al (2009) The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol 157(Suppl 1):3-11
12. Gitt AK, Bueno H, Danchin N et al (2010) The role of cardiac registries in evidence-based medicine. Eur Heart J 31:525-529
13. Gold R, Stangel M, Dalakas MC (2007) Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3:36-44 (Pubitemid 46056032)
14. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J (2009) Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 16:631-638
15. Hughes RA (2009) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial. Expert Rev Neurother 9:789-795
16. Hughes RA, Donofrio P, Bril V et al (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136-144
17. Hughes RA, Dalakas MC, Cornblath DR, Latov N, Weksler ME, Relkin N (2009) Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 158(Suppl 1):34-42
18. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Allgemeine Methoden 3.0 vom 27.5.2008. Internet: http://www.iqwig. de/download/IQWiG-Methoden-Version-3-0.pdf. Cited 12 November 2011
19. Jacob S, Rajabally YA (2009) Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol 7:337-342
20. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J (2011) Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 164 (Suppl 2):2-5
21. Kirch W, Gold R, Hensel M et al (2010) Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods. Med Klin (Munich) 105:647-51
22. Knerr V, Gathmann B, Eades-Perner AM, Kindle G, Grimbacher B (2008) The ESID Online database for primary immunodeficiencies: first analyses with regard to Germany and Europe (in German). Med Klin (Munich) 103:620-627
23. Koller M, Neugebauer EA, Augustin M et al (2009) Assessment of quality of life in health services research: conceptual, methodological and structural prerequisites. Gesundheitswesen 71:864-872
24. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H (2010) Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 125:1354-60 e4
25. Mapi Research Trust Patient-reported Outcome and Quality of Life Instruments Database. Internet: http://www.proqolid.org. Cited 12 November 2011
26. Morfeld M, Bullinger M, Nantke J, Brahler E (2005) The version 2.0 of the SF-36 Health Survey: results of a population-representative study. Soz Präventivmed 50:292-300 (Pubitemid 41684561)
27. National Institute for Clinical Excellence (NICE) (April 2004) Guide to the methods of technical appraisal. London. Internet: http://www.nice.org. uk/niceMedia/pdf/TAP-Methods.pdf. Cited 29 November 2011
28. Plasma Protein Therapeutics Association (PPTA). Certification Program: Quality Standards of Excellence, Assurance, and Leadership (QSEAL). Program Description Version 1.6, 2010. http:// www.pptaglobal.org/UserFiles/file/QSEAL/ QSEAL%20CERTIFICATION% 20PROGRAM%20DESCRIPTION%20V1-6.pdf. Access on 2.2.012
29. Plasma Protein Therapeutics Association (PPTA). International Quality Plasma Program (IQPP) Certification, Program Description Version 2.1 2012. http://www.pptaglobal.org/UserFiles/file/IQPP/ IQPP%20Program%20Description%20V2-1.pdf. Access on 2.2.012
30. Quinti I, Pierdominici M, Marziali M et al (2002) European surveillance of immunoglobulin safety: results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries. Clin Immunol 104:231-236 (Pubitemid 35191098)
31. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O (2008) Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev:CD006501
32. Ravens-Sieberer U, Erhart M, Wille N, Wetzel R, Nickel J, Bullinger M (2006) Generic health-related quality-of-life assessment in children and adolescents: methodological considerations. PharmacoEconomics 24:1199-1220 (Pubitemid 44901676)
33. Schwarz S, Knorr C, Geiger H, Flachenecker P (2008) Complementary and alternative medicine formultiple sclerosis.Mult Scler 14:1113-1119
34. Stangel M (2008) New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. Ther Adv Neurol Disord 1:52-61
35. Stangel MG, Gold R (2010) Administration of intravenous immunoglobulins in neurology: an evidence-based consensus-update 2010 (in German). Nervenarzt 82:415-430
36. Szende A, Leidy NK, Revicki D (2005) Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. Value Health 8:534-548 (Pubitemid 41727305)
37. US Department of Health and Human Services FDA Center for Drug Evaluation and Research (2006) Guidance for industry: patientreported outcome measures-use in medical product development to support labeling claims-draft guidance. Health Qual Life Outcomes 4:79. doi:10.1186/477-7525-4-79